A股異動丨振東製藥跌約12% 股價創近3年新低
振東製藥(300158.SZ)今日盤中一度跌11.93%至3.47元,股價創2021年11月1日以來近3年新低。振東製藥昨日晚間發公吿稱,北京朗迪製藥有限公司就其與本公司涉及的合同糾紛向中國國際經濟貿易仲裁委員會提出仲裁申請。本次申請裁決被申請人向申請人賠償14.67億元人民幣,此金額為申請人申請仲裁金額,該案件尚未開庭,非仲裁結果,最終以仲裁結果為準。值得注意的是,朗迪製藥曾是振東製藥的子公司,2021年公司以58億元的價格出售全資子公司朗迪製藥100%股權給上海方朗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.